# HIPK1: a new immunomodulatory target for SLE

> **NIH NIH R21** · CHILDREN'S HOSP OF PHILADELPHIA · 2024 · $222,500

## Abstract

ABSTRACT
Our prior work using physical maps of systemic lupus erythematosus (SLE)-associated genetic variation in the
context of the 3D structure of the genome in the nucleus of disease-relevant immune cell types have implicated
the kinase HIPK1 as a factor controlling SLE susceptibility. This kinase has been studied in the context of cancer,
but a role for HIPK1 in immunity, tolerance, or SLE has not been explored. In this exploratory, high-risk/high-
impact application we will use genetic and pharmacologic targeting approaches to establish whether HIPK1
regulates T cell differentiation, T cell-dependent humoral immune responses, and SLE pathophysiology in
powerful human and mouse models of follicular lymphocyte differentiation and function. The outcome of these
studies is likely to forward basic understanding of the regulation of humoral immunity and suggest a completely
novel immunomodulatory approach for the management of SLE disease.

## Key facts

- **NIH application ID:** 10893550
- **Project number:** 5R21AI176225-02
- **Recipient organization:** CHILDREN'S HOSP OF PHILADELPHIA
- **Principal Investigator:** ANDREW D WELLS
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $222,500
- **Award type:** 5
- **Project period:** 2023-07-25 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10893550

## Citation

> US National Institutes of Health, RePORTER application 10893550, HIPK1: a new immunomodulatory target for SLE (5R21AI176225-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10893550. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*